Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved.

ABSTRACT:

SUBMITTER: Yoneda M 

PROVIDER: S-EPMC10598311 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature